Literature DB >> 6685579

In vitro interactions of TNO6 with human plasma.

B Hecquet, L Adenis, A Demaille.   

Abstract

The ability of TNO6 to react with human plasma was investigated by in vitro incubation of plasma or plasma fractions with injectable TNO6. HPLC, ultrafiltration and flameless atomic absorption spectrophotometry were used to separate the platinum-containing chemical species and to measure the platinum content. The initial concentration of TNO6 in plasma declines very rapidly. The kinetics of the loss of initial TNO6 is very different from that of cisplatin loss. Most of the TNO6 is bound more quickly to proteins, while a little is transformed to less reactive or nonreactive platinum species. The level of final nonreactive platinum species depends on the particular plasma concerned. In addition, the reactivity of TNO6 towards proteins is very sensitive to Cl- concentration. The usefulness of HPLC for the study of TNO6 kinetics is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6685579     DOI: 10.1007/bf00254200

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  3 in total

1.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.

Authors:  A F LeRoy; R J Lutz; R L Dedrick; C L Litterst; A M Guarino
Journal:  Cancer Treat Rep       Date:  1979-01

Review 3.  Cisplatin: chemistry, distribution and biotransformation.

Authors:  D F Long; A J Repta
Journal:  Biopharm Drug Dispos       Date:  1981 Jan-Mar       Impact factor: 1.627

  3 in total
  5 in total

1.  Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

Authors:  J L Pujol; D Cupissol; C Gestin-Boyer; J Bres; B Serrou; F B Michel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.

Authors:  C Fournier; P Vennin; B Hecquet
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.

Authors:  C Fournier; B Hecquet; G Bastian; D Khayat
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin.

Authors:  B Hecquet; P Vennin; C Fournier; J L Lefebvre; A Caty; J Bonneterre; L Adenis; A Demaille
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.